1-6 of 6
Leo I. Gordon, M.D.
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Bortezomib May Be Safely Combined with Y-90 Ibritumomab Tiuxetan In Patients with Relapsed/Refractory Follicular or Transformed Non-Hodgkin Lymphoma: A Phase I Trial of Combined Induction Therapy and Bortezomib Consolidation

Rupali Roy, M.D., Andrew M Evens, DO, MSc, David P. Patton, B.S., Annette Larsen, B.S., R.N., Alfred Rademaker, Ph.D., Jeffrey Cilley, M.D., Stewart Spies, M.D., Daina Variakojis, M.D., Leo I Gordon, M.D., Jane N. Winter, M.D.
Journal: Blood
Blood (2010) 116 (21): 1749.
https://doi.org/10.1182/blood.V116.21.1749.1749
Published: 2010
Journal Articles

Triggered Release of Nanoparticulate Arsenic Trioxide for Treatment of Malignant Lymphomas: Preclinical Studies

Jane N. Winter, M.D., Dawn Waterhouse, Ph.D., Richard Ahn, Haimei Chen, Leo I. Gordon, M.D., Borko Jovanovic, Ph.D., Marcel Bally, Ph.D., Thomas O’Halloran, Ph.D.
Journal: Blood
Blood (2008) 112 (11): 4989.
https://doi.org/10.1182/blood.V112.11.4989.4989
Published: 2008
Journal Articles

Signaling Pathways of All-Trans Retinoic Acid (ATRA)-Induced Apoptosis in Mantle Cell Lymphoma (MCL).

Amareshwar T.K. Singh, PhD, Savita Bhalla, Ph.D., Robert O. Ryan, Ph.D., Thanh-Son Nguyen, Karthik T.K. Singh, Andrew M. Evens, D.O., Leo I. Gordon, M.D.
Journal: Blood
Blood (2007) 110 (11): 1583.
https://doi.org/10.1182/blood.V110.11.1583.1583
Published: 2007
Journal Articles

Motexafin Gadolinium (MGD) Induces Oxidant Stress and Downregulates Both Pro and Anti-Oxidant Genes in the Ramos Lymphoma Cell Line: Signaling through p53 Mediated Pathways.

Amareshwar T.K. Singh, PhD, Andrew M. Evens, D.O., Qudsia Haque, Sheila N. Prachand, M.S., Karthik T.K. Singh, Leo I. Gordon, M.D.
Journal: Blood
Blood (2007) 110 (11): 4429.
https://doi.org/10.1182/blood.V110.11.4429.4429
Published: 2007
Journal Articles

90 Y Ibritumomab Tiuxetan (Zevalin®; 90 YZ) Doses Calculated To Deliver up to 1500 cGy to Critical Organs May Be Safely Combined with High-Dose BEAM and Autotransplant in NHL.

Jane N. Winter, MD, David Inwards, M.D., Stewart Spies, M.D., Gregory Wiseman, M.D., David Patton, B.S., William Erwin, M.S., Alfred Rademaker, Ph.D., Stephanie Williams, M.D., Martin S. Tallman, M.D., Ivana Micallef, M.D., Jayesh Mehta, M.D., Seema Singhal, M.D., Andrew Evens, D.O., Michael Zimmer, Ph.D., Arturo Molina, M.D., Christine White, M.D., Leo I. Gordon, M.D.
Journal: Blood
Blood (2006) 108 (11): 330.
https://doi.org/10.1182/blood.V108.11.330.330
Published: 2006
Journal Articles

90 Y Ibritumomab Tiuxetan (Zevalin®; 90YZ) Doses Higher Than .4 mCi/kg May Be Safely Combined with High-Dose Beam and Autotransplant: The Role for Dosimetry.

Jane N. Winter, M.D., David J. Inwards, M.D., Stewart Spies, M.D., Gregory Wiseman, M.D., David Patton, William Erwin, M.S., Alfred Rademaker, Ph.D., Stephanie F. Williams, M.D., Martin S. Tallman, M.D., Ivana Micallef, M.D., Jayesh Mehta, M.D., Seema Singhal, M.D., Michael Zimmer, Ph.D., Arturo Molina, M.D., Christine White, M.D., Leo I. Gordon, M.D.
Journal: Blood
Blood (2004) 104 (11): 1162.
https://doi.org/10.1182/blood.V104.11.1162.1162
Published: 2004